Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism
about
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeysAutologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques.Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeysReliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate.Response of aged parkinsonian monkeys to in vivo gene transfer of GDNFThe AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.Aged monkeys as a partial model for Parkinson's disease.Lesion of the centromedian thalamic nucleus in MPTP-treated monkeysCarbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design.Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys.Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.Upregulation of cathepsin D in the caudate nucleus of primates with experimental parkinsonism.Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulationInter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease.NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques.Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonismBalance of increases and decreases in firing rate of the spontaneous activity of basal ganglia high-frequency discharge neurons.Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.Loss of parvalbumin-positive neurons from the globus pallidus in animal models of Parkinson disease.Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates.The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys.Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism.Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.Improved stereotactic procedure enhances the accuracy of deep brain stimulation electrode implantation in non-human primates.MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes.
P2860
Q30498440-634CEDBD-CFC3-4E42-8391-87CC562E9590Q30530883-6A91DFED-C1CC-4BF6-9427-89ACD571A4F8Q30581632-38261D6B-04F9-4711-943C-76EFD4943796Q34214529-02C83081-42F8-4C0F-B2D7-1CC5BD294C62Q34339833-60D6D537-C52E-47FE-8ED2-FD4F195FA58BQ34566620-265AC04C-C3F8-427D-BCCB-4A73B7D9C773Q35163794-4439D27B-B8FE-4ACF-BAA8-19F8F88BED6BQ35551052-10412505-73EA-49E8-9E97-ED3701B434BAQ36496485-0B956151-2624-4108-A6F9-A8A9048E035DQ37192819-E03ADBD3-FA44-41D8-81A6-4648813A475AQ37395632-7595874A-6556-41B6-B5B0-F923EAE47FBAQ38255615-559F779F-CD51-4898-8321-B9DA7FEC6478Q39405720-EE4D76F8-44A7-4169-90BE-AD02AD8FEC79Q40413085-7166138F-66E8-4A16-9B6F-033C723C36F1Q41420806-239500E7-1BD8-4E81-BF5F-8A32C85448B4Q41674970-3C45AC89-8555-44AD-914D-371DA9B06939Q42095959-FCAAACD7-0BE5-416D-88B8-4F2DEF7210B9Q42442871-62DCD684-A278-4508-B8DD-057EB88DBA45Q42487098-7CAFDE26-9E3A-4752-9FA9-846BDED2EA26Q42513867-D130327B-2FF0-4F05-8EE9-C089720234F3Q43653309-E61ABE55-A337-4F6D-9914-1FA8B7C764EBQ44165234-2F7FE9E2-42F6-475E-9D80-1D4A19515041Q45859700-E6FE0FD4-68BD-4C1F-A844-F605D776AFE1Q46670738-C7F98669-0DF4-4731-AA1F-81A525A05706Q48475595-CCF5EC2D-9BEE-471E-A9DC-225B97B293FBQ48683293-1EE93C64-15BF-4621-BB5F-8A322C724282Q49197319-B1DCD8C8-2E5B-4E65-B5A7-84C5863E88B4
P2860
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism
description
1991 nî lūn-bûn
@nan
1991 թուականին հրատարակուած գիտական յօդուած
@hyw
1991 թվականին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@ast
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@en
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@nl
type
label
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@ast
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@en
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@nl
prefLabel
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@ast
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@en
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@nl
P356
P1433
P1476
Oral levodopa dose-response st ...... scale for monkey parkinsonism
@en
P2093
P304
P356
10.1002/MDS.870060205
P407
P50
P577
1991-01-01T00:00:00Z